TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/26/2025
Back to search
Official data from USPTO
BICYCLE RECEPTOR RADIONUCLIDE THERAPY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
BICYCLE RECEPTOR RADIONUCLIDE THERAPY
ST13
US500000079340794Class
5, 42, 44
Filing
79340794
Registration
7159644
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
33
Latest update
04/02/2025
Classification
Registered
Trademark type
Word
Nice classes
5, 42, 44
Filing date
02/25/2022
Registration date
09/12/2023
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/12/2023
Last transaction
04/02/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
GB
Examiner
LEASER, ANDREW
Law office
M80
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Bicycletx Limited
Representatives
Christina M. Licursi Wolf, Greenfield & Sacks, P.C.
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceuticalsfor use in the treatment and prevention of disease in the field of oncology for both solid and liquid tumoursfor use in the treatment and prevention of metabolic diseaseurology and renal diseasein the cardiovascular fieldin the field of hematologyfor use in the treatment and prevention of respiratorychronic and acute inflammatory disease and auto-immune disordersgastrointestinal diseasebacterial and viral infectious diseaseneurological and psychiatric disorders; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of oncology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of ophthalmology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of neurology; anti-infective pharmaceutical products and preparations; pharmaceutical products and preparations for the treatment and/or prevention of respiratory disease; pharmaceutical products and preparations for the treatment and/or prevention of cardiovascular disease; pharmaceutical products and preparations for the treatment and/or prevention of metabolic disease; pharmaceutical products and preparations for the treatment and/or prevention of viral infections; pharmaceutical products and preparations for use in diagnostics and imagingclinical imaging agents; pharmaceutical products and preparations for the treatment and/or prevention of renal disease; pharmaceutical products and preparations for the treatment and/or prevention of gastrointestinal disease; pharmaceutical products and preparations for the treatment and/or prevention of muscular skeletal disease
Class 42
Scientific and technological services and research and design relating theretoscientific researchnew product design servicesnew study design services in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumorsmetabolic diseaseurology and renal diseasecardiovascularhematologyrespiratorychronic and acute inflammatory disease and auto-immune disordersgastrointestinal diseasebacterial and viral infectious diseaseneurological and psychiatric disordersdiagnostic preparations and clinical imaging agents; industrial analysis and research services in the fields of oncology for both solid and liquid tumorsmetabolic diseaseurology and renal diseasecardiovascularhematologyrespiratorychronic and acute inflammatory disease and auto-immune disordersgastrointestinal diseasebacterial and viral infectious diseaseneurological and psychiatric disordersdiagnostic preparations and clinical imaging agents; pharmaceutical research and development services; medical research and development services; pharmaceutical testing and medical and scientific researchconducting clinical trials for others; medical and scientific researchconducting clinical trials for others; research and development in the field of oncology; research and development in the field of ophthalmology; research and development in the field of neurology; research and development in the field of anti-infective pharmaceuticals; research and development in the field of respiratory disease; research and development in the field of cardiovascular disease; research and development in the field of metabolic disease; research and development in the field of antiviral drugs; research and development in the field of diagnostics and imaging; research and development in the field of renal disease; research and development in the field of gastrointestinal disease; research and development in the field of muscular skeletal disease; information consultancy and advisory services relating to the aforesaid
Class 44
Medical services; medical testing for diagnostic or treatment purposes; healthcare services for the treatment and prevention of disease in the field of oncology for both solid and liquid tumoursfor the treatment and prevention of metabolic diseaseurology and renal diseasecardiovascular diseasesfor the treatment and prevention of disease in the field of hematologyfor the treatment and prevention of respiratorychronic and acute inflammatory disease and auto-immune disordersgastrointestinal diseasebacterial and viral infectious diseaseneurological and psychiatric disorders; pharmaceutical compounding services; medical consulting services; advisory services relating to pharmaceuticals; consultancy and information services relating to pharmaceuticalsmedical and pharmaceutical consultation and providing information relating to diagnosticprophylactic and therapeutic properties of pharmaceuticals; medical services in the field of oncology; medical services in the field of ophthalmology; medical services in the field of neurology; medical services in the field of anti-infectives; medical services in the field of respiratory disease; medical services in the field of cardiovascular disease; medical services in the field of metabolic disease; medical services in the field of the treatment and/or prevention of viral infections; medical services in the field of diagnostics and imaging; medical services in the field of renal disease; medical services in the field of gastrointestinal disease; medical services in the field of muscular skeletal disease; pharmaceutical compounding services in the field of oncology; pharmaceutical compounding services in the field of ophthalmology; pharmaceutical compounding services in the field of neurology; pharmaceutical compounding services in the field of anti-infectives; pharmaceutical compounding services in the field of respiratory disease; pharmaceutical compounding services in the field of cardiovascular disease; pharmaceutical compounding services in connection with metabolic disease; pharmaceutical compounding services in connection with the treatment and/or prevention of viral infections; pharmaceutical compounding services in connection with diagnostics and imaging; pharmaceutical compounding services in connection with renal disease; pharmaceutical compounding services in connection with gastrointestinal disease; pharmaceutical compounding services in connection with muscular skeletal disease; informationconsultancy and advisory services relating to the aforesaid
Publications
History of USPTO decisions and trademark events.
33 publications found
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
03/26/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/26/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/26/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
03/26/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
03/26/2025
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/08/2024
FICS
FINAL DISPOSITION NOTICE SENT TO IB
12/14/2023
FIMP
FINAL DISPOSITION PROCESSED
12/14/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
12/12/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/01/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/12/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
09/12/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/27/2023
PUBO
PUBLISHED FOR OPPOSITION
06/27/2023
GPNX
NOTIFICATION PROCESSED BY IB
06/26/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
06/07/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
06/07/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/07/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/22/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/21/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/20/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/20/2023
RFNT
REFUSAL PROCESSED BY IB
11/21/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
10/28/2022
RFRR
REFUSAL PROCESSED BY MPU
10/28/2022
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
09/24/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/11/2022
CNRT
NON-FINAL ACTION WRITTEN
09/10/2022
DOCK
ASSIGNED TO EXAMINER
09/07/2022
MAFR
APPLICATION FILING RECEIPT MAILED
05/24/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/20/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
05/19/2022
Continuous trademark protection
Get notified about every new filing that threatens BICYCLE RECEPTOR RADIONUCLIDE THERAPY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.